Summary Background: There is no standard treatment for patients with locally advanced esophageal carcinoma without systemic metastasis in whom surgery is no longer considered a reasonable option. Patients and Methods: Patients with cervical esophageal tumors, locally very advanced stage (T4 and/or M1a) or locally advanced (T3 and/or N+) with comorbidities were included. Therapy: 2 cycles of induction chemotherapy (cisplatin and docetaxel, both 75 mg/m 2 3-weekly) followed by chemoradiation therapy (CRT) comprising a total radiation dose of 59.4 Gy together with docetaxel 15 mg/m 2 and cisplatin 25 mg/m 2 (5 weekly doses). Primary endpoint: Histologically proven freedom from local failure 6 months after CRT completion. Results: 21 patients were included: 12 had locally very advanced tumors, 3 had cervical esophagus tumors, and 6 were medically unfit for surgery. 18 patients completed therapy per protocol. Grade 3/4 toxicities during CRT were thrombopenia (10%) and dysphagia (15%). 1 patient died due to herpes simplex infection. The primary endpoint was achieved by 4 patients, 6 were alive after median follow-up of 34 months, and median survival was 16 months. Most patients experienced lasting improvement of dysphagia following induction chemotherapy. Conclusions: This regimen is feasible, showed clinically meaningful, long-lasting improvements in quality of life and resulted in long-term survival in 29% of the patients.
Patienten erhielten die gesamte Therapie gemäß Protokoll. Die häufigsten Grad-3/4-Toxizitäten während der CRT waren Thrombopenie (10%) und Dysphagie (15%). Ein Patient verstarb an einer Herpes-simplex-Hepatitis. 4 Patienten erreichten den primären Endpunkt, nach 34 Monaten Nachbeobachtungszeit waren 6 noch am Leben, das mediane Überleben betrug 16 Monate. Die durch die Patienten erfasste Dysphagie zeigte eine anhaltende Verbesserung nach der Induktionschemotherapie. Schlussfolgerungen: Die geprüfte Therapie war gut durchführbar und zeigte eine klinisch relevante Verbesserung der Lebensqualität sowie ein Langzeitüberleben bei 29% der Patienten.
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Introduction
Esophageal cancer ranks sixth among the causes of death from cancer worldwide [1] . Most patients with newly diagnosed carcinoma of the esophagus present with potentially resectable, locally advanced disease. The accepted standard treatment for these patients is potentially curative therapy comprising neoadjuvant chemoradiation (CRT) or chemotherapyfollowedbysurgeryanddefinitiveCRT [2] [3] [4] [5] .Aminorityofpatientspresentwithsystemicmetastasisatdiagnosisandareusuallytreatedwithchemotherapyoronlypalliative care [6] . However, there is a specific group of patients withlocallyadvanceddisease,withoutsystemicmetastases,in whom the disease is still regional, but surgery is no longer considered a reasonable option because of tumor location (cervical esophagus), very advanced stage (M1a or T4) or poorperformancestatusandcomorbidities.Multidisciplinary team meetings to determine the best treatment strategy for such patients usually focus on the difficult question of how muchtherapycouldorshouldbegivenwhenthereisnohope forsurgicalcure.Therangeofoptionsincludesradiotherapy (externalbeamorbrachytherapy),moreintensiveCRT,systemicchemotherapy,stentinginterventions,oronlypalliative care.Substantialpalliationofdysphagiacanbeachieveddespitetheoftenrelativelypoorconditionofsuchpatients;however,mostwillexperiencetumorprogressionattheprimary site.Therearefewprospectivetrialsfocusingonthisspecific population [7, 8] .Someofthesepatientsdeemedtobeinoperable have been included in trials of CRT for locally advanceddisease [2, [9] [10] [11] .Thesestudiesprovidedevidenceto suggestimprovedoverallsurvivalforthewholegroupofpatientstreatedwithCRTcomparedwithradiotherapyalone.
Based on these considerations, we initiated a prospective nationwide,multicentertrialtoinvestigatewhetheranintensive treatment strategy using induction chemotherapy followedbyCRTisfeasibleandbeneficialforthisspecificgroup ofpatientswithinoperableloco-regionalesophagealcancer.
Patients and Methods
Thiswasaprospective,open-label,multicenterphaseIIstudyconducted bytheSwissGroupforClinicalCancerResearch(SAKK).Theprotocol wasapprovedbythelocalethicscommitteeofeachparticipatinginstitution, and all patients gave their written informed consent before registration.
Major Eligibility Criteria
Previouslyuntreatedpatientswithhistologicallyconfirmedsquamouscell carcinomaoradenocarcinomaoftheesophaguswereeligibleifthetumor was:(1)locallyveryadvanced(T4and/orM1a),(2)locatedinthecervical esophagealregion,or(3)locallyadvanced(T3and/orN+)butthepatient wasmedicallyunfitforsurgery.Alltumorlesionshadtobeencompassable in a single radiation port. Patients with distant metastases were excluded.Furtherselectioncriteriaincludedagebetween18and70years,a WorldHealthOrganization(WHO)performancestatus<2,andnormal organfunction.
Treatment Schedule and Evaluation Plan
Pretreatmentstagingconsistedofcompletemedicalhistory,physicalexamination, upper endoscopy with biopsy, helical computed tomography (CT) scans of the chest and abdomen (and neck for cervical or upper thirdthoracallocalization),endoscopicultrasound(EUS),andbronchoscopyfortumorsaboveoratthetrachealbifurcation.Alaparoscopyfor tumorsofthelowerthirdoftheesophaguswasoptional.Positronemission tomography (PET) or PET-CT staging was recommended, but not mandatory.
Treatment consisted of induction chemotherapy followed by CRT ( fig.1 ).Inductionchemotherapyconsistedof2cyclesofintravenousdo-cetaxelandcisplatin,both75mg/m 2 onday1ofa3-weeklycycle.CRT wasstartedaftercompletionofthesecondinductionchemotherapycycle. Three-dimensional (3D) conformal radiotherapy delivering a total dose of59.4Gy(33fractionsof1.8Gy)wasgivenover7weekswithaminimal energyof6-MVphotons.Theplannedtargetvolumeincludedallknown areasofdiseasewitha5-cmcranialandcaudalmarginanda2-cmlateral margin. Concomitant chemotherapy consisted of intravenous docetaxel 15mg/m 2 andcisplatin25mg/m 2 administeredweeklyfor5weeksonan outpatientbasis.
Dose Modifications and Follow-up
ToxicitywasgradedaccordingtotheNationalCancerInstitute-Common Toxicity Criteria (NCI-CTC) version 2.0. In the second induction chemotherapycycle,cisplatinanddocetaxelwerebothpostponedifthe absoluteneutrophilcount(ANC)was<1500/mlortheplateletcountwas <100,000/ml.PatientswererequiredtohaveanANCof≥1000/mlanda platelet count of ≥ 75,000/ml prior to starting CRT. During CRT, docetaxelwasomittedfor1weekiftheANCwas<1000/mlortheplatelet countwas<50,000/ml.Radiotherapyandbothdrugswereomittedfor1 
Results

Patient and Tumor Characteristics
Thestudywasstoppedprematurelyafteraninterimanalysis when 21 patients from 7 Swiss cancer centers were enrolled (table1).Mostpatientsweremen(86%),themedianagewas 64.3 years (range 45.8-73.1 years), and 11 had the performancestatus0.PET-CTwasusedforstagingin14(67%)patients.Thereasonsforinclusioninthistrialwereasfollows: 12(57%)patientshadlocallyveryadvanceddisease(T4and/ orM1a),3(14%)hadatumorinthecervicalesophagus(T4 in 1), and 6 (29%) had locally advanced tumors (T3 and/or N+)butweremedicallyunfitforsurgery.Histologywassquamouscellcarcinomain10(48%),adenocarcinomain8(38%) andmixed/undifferentiatedcarcinomaintheremainingcases.
Feasibility and Toxicity
All21patientsreceived2fullcyclesofinductionchemother-apyand18(86%)receivedthefullcourseofCRTaccording to the predefined feasibility endpoint. Peracute fatal herpes simplex hepatitis developed in 1 patient (unique patient number(UPN)17)4weeksafterthestartofCRT [18] .Anotherpatient(UPN19)didnotstartCRTbecausethetumor volume was too large according to the radiooncologist and, therefore,retrospectivelythispatientwouldnothavemetthe trialinclusioncriteria.Radiotherapywasstoppedearly(after 39.6Gy)inathirdpatient(UPN15)becausetheradiooncologist was concerned about intolerable late sequalae resulting fromaverylargeirradiationvolume.
ThetoxicityprofileofinductionchemotherapyandCRT islistedintable2.Toxicitiesduringinductionchemotherapy were as expected and manageable. Hematologic toxicity was the most common adverse event occurring to some degree in all patients receiving 2 cycles of docetaxel and cisplatin. Second-cycle chemotherapy dose reductions of 25% were required for docetaxel (1 patient) and both docetaxel andcis platin(2patients)asaresultofinfection,weightloss or stomatitis. CRT was well tolerated by most patients. Grade3/4thrombopeniaoccurredin2patientsanddysphagia in3patients. weekiftheANCwas<500/mland/ortheplateletcountwas<25,000/ml afterweeklyreassessment.Docetaxelwasomittediffebrileneutropenia occurredduringCRT,whereasradiotherapyandcisplatinwerecontinuedatthediscretionofthelocalinvestigator.Earlyinsertionofafeeding tube was recommended for patients developing tumor-or treatmentinduceddysphagia.Radiotherapywascontinuedinpatientswithgrade3 therapy-induced esophagitis, but the final decision to continue chemotherapywaslefttothelocalinvestigator.Bothchemotherapyandradiationwereomittedinpatientswithgrade4esophagitisuntiltoxicityre-solvedtograde3. Cisplatinwasreplacedbycarboplatininpatientsdevelopinggrade3 peripheralneuropathy,grade2hearingimpairment,orcreatinineclearance<50ml/min.Carboplatinwasgivenatadoseofareaundertheconcentration-timecurve(AUC)6mg•min/mlforthesecondcycleofinductionchemotherapyandAUC2mg•min/mlthroughoutCRT.Dosereductionruleswereappliedforgrade3nausea,vomitingordiarrhea.
Follow-up including CT scans, physical examination, evaluation of adverse events, and quality-of-life (QoL) assessment was carried out 3-monthlyduringthefirstyearfollowingcompletionofCRT,6-monthly duringthenext3years,andsubsequentlyonanannualbasisunlessotherwiseclinicallyindicated.Endoluminalultrasoundandendoscopywithat least4biopsiesoftheprevioustumorareawerescheduled6monthsafter completion of CRT. Further endoscopic examinations were performed only in patients presenting with symptoms raising suspicion of local failure.
Endpoints and Criteria for Response and Survival
The main objective of this trial was to evaluate whether intensive CRT afterinductionchemotherapycanachieveahighrateoflocalcontrolwith acceptabletoxicityandstableQoLinpatientswithlocallyadvancedesophageal cancer. To test this hypothesis, we selected the primary endpoint 'percentage of patients with histologically proven freedom from localfailure6monthsafterthelastdoseofradiotherapy',definedasthe absenceofprimarytumorandanynewlesionorrecurrencebyradiological means within the radiotherapy field. In all patients without signs of tumor,atleast4biopsieshadtobetakenfromtheareaoftheprimary tumor.Wedefinedafeasibilityendpointtoevaluatethecomplianceand toxicityofthistreatment.Thefeasibilityendpoint,basedonanintentionto-treatanalysis,wasdefinedasfollows:theproportionofpatientsalive 30 days after the end of therapy and completing the whole therapeutic regimen comprising 2 cycles of induction therapy and at least 50 Gy of radiotherapytogetherwithatleast4cyclesofweeklyconcomitantchem-otherapy(evenifthereweredosereductionsoronlyonedrugwasadministered).Overallsurvivalwasasecondaryendpoint.Thepatternoffailure wasdeterminedbythelocalizationofthetumoratthetimeofrelapse.
Quality of Life
Symptom-specifickeyaspectsofQoLinthissituation(i.e.dysphagiaand problemswitheating)wereassessedbytheEuropeanOrganisationfor Research and Treatment of Cancer (EORTC) QoL module specific to esophageal cancer (QLQ-OES24) [12, 13] . In addition, two global QoL indicatorsforphysicalwell-beingandcopingeffortweremeasuredwith linear analog self-assessment (LASA) scales [14, 15] . All scales range from 0 to 100, with higher scores representing more symptoms with respect to dysphagia and eating problems, but better physical well-being andlesscopingeffort.
Statistics
Toevaluatetheprimaryendpoint'percentageofpatientswithhistologically proven freedom from local failure 6 months after the last dose of radiotherapy',thesamplesizewascalculatedtohaveapowerof80%and asignificancelevelof5%toacceptanineffectivetreatment.Thisstudy usedatwo-stagedesignbasedonHerndon'sapproach,amodificationof Simon's 2-stage design that allows continued accrual while waiting for stage-1results [16] .A≥50%rateoffreedomfromlocalfailurewascon- Anemia  21  100  1  5  20  100  1  5  Leukopenia  12  57  6  29  10  50  1  5  Neutropenia  8  38  6  29  3  15  1  5  Thrombopenia  9  43  1  5  17  85  2  10  Dysphagia  16  76  1  5  18  90  3  15  Stomatitis  3  14  1  5  0  0  0  0  Diarrhea  8  38  1  5  2  10  0  0  Nausea  5  24  1  5  8  38  0  0  Vomiting  3  14  1  5  2  10  0  0  Alopecia  13  62  0  0  17  81  0  0  Asthenia  14  67  0  0  12  57  0  0  Neurosensory  1  5  0  0  2  10  0  0  Other  17  81  4  19  18  90  2  10 Themedianscoresforphysicalwell-beingremainedwithin thehighestquartileoverthewholeobservationperiod,representingarathergoodoverallphysicalwell-beingduringtreatment and for up to 9 months after treatment, followed by a smalldeclineuptothe12-monthfollow-up.Aclinicallymeaningful improvement in coping effort was observed during treatment(medianchangeof+19)andthescoresremainedat thislevelfor9monthsaftertreatment.
Discussion
We prospectively identified a difficult-to-treat group of patientswithesophagealcarcinomaanddiseasestatusbetween locallyadvancedandmetastaticforwhomthereisnostandard treatment and therapy is often considered palliative. In thisgroupofpatients,weprospectivelyinvestigatedthevalue afterradiotherapyforanyreason(e.g.previousdilatationof theesophagus,patientrefusal).1patient(UPN5)refusingbiopsiesremaineddiseasefreeformorethan3yearsafterregis-tration.Therefore,itcanbeassumedthatoverall5of21pa-tients(24%)remainedfreeoflocalandsystemicrecurrence6 monthsaftertheendofCRT.
Of the other patients, 1 died of herpes simplex hepatitis duringCRT(UPN17),asdescribedabove,and2diedafter CRT but before assessment at 6 months, 1 due to local and systemicprogression(UPN2)and1duetomultiorganfailure after salvage surgery for persistent local tumor (UPN 8). In theremaining12patientshavingfinishedCRT,therewere9 (43%) local failures and 3 (19%) systemic and local failures ( fig.1 ).ThepatientwhodidnotreceiveCRT(UPN19)experiencedsystemicandlocalfailure.
Afteramedianfollow-upof33.7months(95%confidence interval (CI) 29.4-38.2 months), 6 (29%) patients were still alive, including 2 with proven local residual disease after CRT,1ofwhom(UPN18)receivedsubsequentsalvagesurgery. There were 12 (57%) deaths from progressive disease and 3 (14%) from non-disease-related causes (table 1) . Median overall survival was 15.8 months (95% CI 12.3-25.6 months). The rates of 1-, 2-and 3-year survival were 71%, 38%, and 29%, respectively ( fig. 2 ). Of the 6 surviving patients,4hadlocallyveryadvanceddiseaseatinclusionandthe other2hadbeenclassifiedasinoperableformedicalreasons. Of note, all of these patients were doing well at the time of writing and 4 had no or only minimal dysphagia 12 months aftercompletionoftreatment.
Quality of life
Figure3presentsthescoresfordysphagia,problemswitheating,physicalwell-being,andcopingeffortatbaseline,during therapy,and3,6,9,and12monthsaftercompletionoftreat-ment. At baseline, i.e. before treatment started, all patients (100%)completedthequestionnaire.Thecompletionrateremainedabove80%throughoutthetreatmentphase.Non-submitted QoL questionnaires were missing due to administrativeerrors(i.e.questionnairenotpresentedtothepatient).At the 6-month follow-up, 65% of the surviving patients completed the questionnaire. Except in 1 case, all patients who broad term 'inoperable' [7, 11, 25] . In these studies, there were many diverse reasons for patients being considered inoperable, including older age, comorbidity, advanced stage and the presence of systemic disease. Additionally, not all studies used modern staging methods. The heterogeneity of the inclusion criteria of these studies is reflected by the reported median survival rates widely ranging from 6 to 26 months.However,inoneretrospectiveseries [25] ,about20% ofpatientswithT4stagesweredescribedaslong-termsurvivors after CRT as well. None of the 3 patients with cervical esophageal tumors included in the present trial were in the group of long-term survivors. Histology did not predict outcome, and long-term survival was achieved in patients with adenocarcinomaorsquamouscellcarcinoma. Despitetheintensetreatmentschedule,QoLwasimpaired onlytemporarilyinthemajorityofpatients.Ofnote,evenpatientsexperiencingrelapsehadnoorminordysphagiaovera periodof9monthsaftertheendoftreatment.
Weconcludethatthisintensetreatmentscheduleisfeasibleinpatientswithlocallyadvancedesophagealcancerthatis not amenable to potentially curative resection. Moreover, somepatientsinthispoor-prognosisgroupcanachievelongtermsurvivalwiththisintensivetherapy.Althoughthespecified primary endpoint of confirmed local control after 6 months was not met, there was evidence of clinical benefit. Specifically, we observed that relapsing patients also benefitedfromtreatment,asshownbyimprovementsinQoLparameters(dysphagiaandproblemswitheating)andthemaintenanceofgoodandstablephysicalwell-beingforaconsiderableperiodaftertheendoftreatment.Inductionchemotherapy and CRT may be an option for selected patients with locallyveryadvanceddisease.However,theselectionofpatientsforintensivetherapyremainsdifficult.Thepresentdata are limited in this regard because patients with both adenoand squamous cell carcinoma were among the survivors, whereas patients with cervical cancer were not represented, possibly due to an inadequate number of patients enrolled. Furtherstudiesarewarranted,particularlytoidentifypredictivefactorstojustifysuchanintensetherapyinthosepatients mostlikelytobenefit.
